Northwest Biotherapeutics (NWBO) Notes Payables (2010 - 2026)

Northwest Biotherapeutics' Notes Payables history runs 17 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• On a quarterly basis, Notes Payables rose 1024.52% year-over-year to $11.6 million in Q1 2026; TTM through Mar 2026 was $11.6 million, a 1024.52% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, up 326.68% from the prior year.
• Notes Payables improved to $11.6 million in Q1 2026 per NWBO's latest filing, from $9.5 million in the prior quarter.
• Across five years, Notes Payables topped out at $98.6 million in Q1 2022 and bottomed at $913000.0 in Q1 2024.
• The 5-year median for Notes Payables is $8.9 million (2024), against an average of $19.4 million.
• Across the five-year window, Notes Payables plunged 98.62% in 2023 and jumped 1024.52% in 2026, its largest moves.
• Year by year, Notes Payables stood at $15.4 million in 2022, then tumbled by 93.87% to $944000.0 in 2023, then surged by 135.06% to $2.2 million in 2024, then surged by 326.68% to $9.5 million in 2025, then increased by 23.05% to $11.6 million in 2026.
• Per Business Quant, the three latest NWBO Notes Payables figures stand at $11.6 million (Q1 2026), $9.5 million (Q4 2025), and $13.6 million (Q3 2025).